GlassScriptPhysician profile
Kathryn Helson
NPI 1134872542
$4,704.30
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $838 · 2023: $1,604 · 2024: $1,769 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,805.95 | 2022-2025 | |
| Novo Nordisk INC | $548.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $357.26 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $202.16 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Jazz Pharmaceuticals INC. | $193.24 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $180.55 | 2023-2025 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $161.62 | 2022-2023 | |
| Alkermes, INC. | $158.75 | 2023 | Lybalvi |
| Exact Sciences Corporation | $148.61 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $111.17 | 2024 | Hetlioz, Fanapt |
| Lilly USA, LLC | $107.09 | 2022-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $106.17 | 2023-2024 | |
| Astellas Pharma US INC | $77.35 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $58.81 | 2022 | |
| Amgen INC. | $55.24 | 2022-2023 | Aimovig |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $50.85 | 2024 | Gemtesa |
| Lundbeck LLC | $47.05 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.88 | 2023-2025 | Xifaxan, Trulance |
| Nevro Corp. | $35.91 | 2023 | Senza |
| Ardelyx, INC. | $35.22 | 2023-2024 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $33.17 | 2023-2025 | Quviviq, Quviviq |
| Baxter Healthcare | $22.50 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Phadia US INC. | $20.50 | 2024 | Immunocap |
| Phathom Pharmaceuticals, INC. | $20.34 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.31 | 2025 | Caplyta |
| Bausch Health US, LLC | $18.86 | 2023 | Aplenzin, Wellbutrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.78 | 2022 | |
| Axsome Therapeutics, INC. | $18.09 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $14.36 | 2023 | Verquvo, Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $14.10 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Helson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.